Tocilizumab

Active substance
Tocilizumab
Domain
Chronic immune diseases
Reason of inclusion in Horizonscan Geneesmiddelen
Biosimilar
Main indication
Rheumatism
Extended indication
Rheumatoid arthritis (RA), giant lymph node hyperplasia (Castlesman’s disease), polyarticular idioathic juvenile arthritis (PJIA) and systemic juvenile idiopathic arthritis (SJIA).

1. Product

Current proprietary name
RoActemra (Roche)
Proprietary name
LusiNEX
Manufacturer
Mycenax Biotech
Mechanism of action
Interleukin inhibitor

2. Registration

Registration route
Centralised (EMA)
Orphan drug
No
Registration phase
Clinical trials
Additional comments
Momenteel loopt er een fase 1 studie (NCT03522012). SPC RoActemra verloopt op 6 juni 2020.

3. Therapeutic value

Therapeutic value
Potential equal value
Duration of treatment
Not found

4. Expected patient volume per year

Patiëntvolume is niet van toepassing bij generieke geneesmiddelen of biosimilars.

5. Expected cost per patient per year

Horizonscan vermeldt geen prijsinformatie van generieke geneesmiddelen of biosimilars om het eventueel beïnvloeden van de markt te voorkomen.

6. Potential total cost per year

Horizonscan vermeldt geen prijsinformatie van generieke geneesmiddelen of biosimilars om het eventueel beïnvloeden van de markt te voorkomen.

7. Off label use

There is currently nothing known about off label use.

8. Indication extension

There is currently nothing known about indication extensions.

9. Other information

There is currently no futher information available.